GfK Healthcare Expands TCD Studies to BRIC Region

GfK Healthcare is rolling out its syndicated TCD physician studies, until now focused on the US and Europe, to Brazil, Russia, India and China (BRIC). The studies will offer local market treatment perspectives across cardiovascular, psychiatry, respiratory and rheumatology/pain specialisms.

The firm has produced TCD (Therapeutic Class Dynamics) studies in the US for more than 45 years, across a broad range of therapeutic categories. Recently, the program was expanded to cover EU markets in France, Germany, Italy, Spain and the UK.

TCD studies provide brand teams with perspectives from key prescribers including insights on patient volume, prescribing and switching behavior, and unmet market needs, as well as physician perceptions, attitudes and actions.

These insights are used to inform a wide range of business issues such as the development of branding and competitive strategies, the evaluation of merger and co-promotion opportunities, and the assessment of new compounds.

Heinz Ohde, Manager, Global Syndicated Services, GfK HealthCare, comments: 'Using a multi-client approach, together with the efficiency of online research, we are able to use TCD to deliver deep local market insights into therapeutic areas at a reasonable cost. Our expansion of TCD into Europe and now the BRIC markets speaks to the value these studies have created for dozens of global pharmaceutical companies.'

Next year, TCD studies will also be conducted in Japan.

Web site: www.gfkhc.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• GfK Germany
• All news